Treatment of Acute Lymphoblastic Leukemia in Children
NCT00400946
Completed
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis. We have previously reported that patients with acute lymphoblastic leukemia in whom asparaginase treatment was discontinued because of intolerable side-effects had survival outcomes that were inferior to those who received all or nearly all of their intended doses. Two bacterial sou... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
11/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +7 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia
Register for Updates
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
NCT05192889
Active Not Recruiting
This is a phase I/II clinical trial evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) and assessing the combination dose of venetoclax combinations with either blinatumomab for CD19-postive patients or navitoclax and high-dose cytarabine for CD19-negative patients. Primary Objectives * To compare Minimal Residual Disease (MRD)-negative CR/CRi rate in children with relapsed o... Read More
Gender:
ALL
Ages:
Between 4 years and 30 years
Trial Updated:
11/22/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Register for Updates
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
NCT03576547
Completed
This phase I/II trial studies the best dose of venetoclax when given together with ponatinib and dexamethasone and to see how well they work in treating participants with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, t(9;22)
Register for Updates
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02199665
Recruiting
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blockin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Mayo Clinic (AZ), Scottsdale, Arizona +4 locations
Conditions: Refractory Multiple Myeloma
Register for Updates
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05789303
Recruiting
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Multiple Myeloma, Relapse Multiple Myeloma
Register for Updates
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients with Refractory Multiple Myeloma
NCT03713294
Completed
This phase II trial studies how well dexamethasone, elotuzumab, pomalidomide work in treating patients with multiple myeloma that has not responded to previous treatment. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as elotuzumab, may help the body's immune system attack the cancer, and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Refractory Plasma Cell Myeloma
Register for Updates
Regulation of Insulin Secretion by the GLP-1 Receptor
NCT02844907
Terminated
AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance. Healthy subjects will have fasting GLP-1 action determined with GLP-1r blockade before and after induction of experimental insulin resistance. The investigators hypothesize that fasting GLP-1 action will increase to compensate for experimental insulin resistance. AIM3: The purpose of Aim-3 of this study is to determine the role of basal GLP-1 action on fasting... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/19/2024
Locations: Durham VA Medical Center, Durham, NC, Durham, North Carolina
Conditions: Insulin Secretion
Register for Updates
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551
Recruiting
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
NCT02057380
Completed
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Site US10004, La Jolla, California +11 locations
Conditions: Advanced Solid Tumors
Register for Updates
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT06050512
Withdrawn
Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases. While still considered an incurable disease, new treatments have improved outcomes dramatically over the last two decades. Around the turn of the millennium, classical cytotoxic chemotherapy and radiation were the only available treatment modalities and median OS was estimated at 2-3 years. Currently, there are now 17 FDA-approved anti-myeloma agents and median OS is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Relapsed and Refractory Multiple Myeloma
Register for Updates
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01665794
Active Not Recruiting
The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +4 locations
Conditions: Multiple Myeloma
Register for Updates
Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema (DIAMOND-1)
NCT05066997
Recruiting
The primary objective is to evaluate the efficacy and safety of OCS 01 as compared to Vehicle in subjects with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/14/2024
Locations: Oculis Investigative Site: University Retina - Lemont, Lemont, Illinois
Conditions: Diabetic Macular Edema
Register for Updates